Brendan Glackin Named a Top Antitrust Lawyer in California by the Daily Journal

We are pleased to announce that the Daily Journal (subscription) has named Lieff Cabraser partner Brendan Glackin to its just-announced Top Antitrust Lawyers in California for 2025 list. Brendan is one of only 35 antitrust law practitioners in the state selected for the list, and the profile published today spotlights his past successes and ongoing case work.

You can read Brendan’s profile on the Daily Journal website (subscription required).

Congratulations to Brendan on this prestigious and well-deserved accomplishment!

About Brendan Glackin

The Chair of Lieff Cabraser’s Antitrust practice group, Brendan Glackin has represented direct purchasers of titanium dioxide in a nationwide antitrust class action lawsuit ($163.5 million in settlements); direct purchasers of flat-panel TV screens in litigation against the world’s leading LCDs manufacturers for conspiring to fix prices ($470 million in settlements; retailers in a monopolization pricing lawsuit against Abbott Laboratories charging that the company exploited the market for AIDS medicines used in conjunction with Abbott’s prescription drug Norvir, and employees in the high-tech workers class action alleging that major Silicon Valley firms colluded to reduce competition for workers.

Brendan has contributed groundbreaking work in litigation against drug makers for blocking access to affordable generics. This includes the blockbuster brand-name prescription drug Cipro ($399 million in settlements), which led to a 2016 “California Lawyer Attorney of the Year” (CLAY) award. Brendan continued his work in the field of generic drugs as lead counsel for Nashville General Hospital (the Hospital Authority of Metropolitan Government of Nashville) in a class-action antitrust case against defendants for monopolizing enoxaparin, the generic version of the blockbuster life-saving anti-coagulant Lovenox, which in 2019, settled for $120 million, the second largest indirect-purchaser antitrust pharmaceutical settlement fund in history, after Cipro.